CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -18.85% and -78.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?